Freeman R W, Uetrecht J P, Woosley R L, Oates J A, Harbison R D
Drug Metab Dispos. 1981 May-Jun;9(3):188-92.
Procainamide (PA) formed reactive metabolites capable of covalently binding to protein both in vivo and in vitro. The in vitro covalent binding of PA to washed hepatic microsomal protein prepared from control male mice was dependent upon mixed-function oxidase activity. The binding was proportional with time and protein concentration. Glutathione and SKF 525-A inhibited the in vitro covalent binding by 88 and 51%, respectively. The addition of NaF to the incubation medium produced a concentration-dependent decrease in covalent binding. Covalent binding of N-acetylprocainamide in vitro was 90% less than that of procainamide and was not increased by NaF. The in vivo covalent binding of PA to hepatic protein in male mice was increased with phenobarbital and 3-methylcholanthrene pretreatment, resulting in increase in binding of 29 and 56%, respectively, compared to control mice. Pretreatment of mice with SKF 525-A inhibited binding by 39%. Depletion of hepatic glutathione with diethyl maleate pretreatment increased the amount of covalent binding in vivo. Bioactivation of PA by hepatic microsomal enzymes in the mouse produces a metabolite capable of covalent interactions with cellular macromolecules.
普鲁卡因酰胺(PA)在体内和体外均能形成可与蛋白质共价结合的反应性代谢产物。PA与从对照雄性小鼠制备的洗涤过的肝微粒体蛋白的体外共价结合依赖于混合功能氧化酶活性。这种结合与时间和蛋白质浓度成正比。谷胱甘肽和SKF 525 - A分别抑制体外共价结合88%和51%。向孵育培养基中添加氟化钠会使共价结合呈浓度依赖性降低。N - 乙酰普鲁卡因酰胺的体外共价结合比普鲁卡因酰胺少90%,且不受氟化钠影响。雄性小鼠体内PA与肝蛋白的共价结合在苯巴比妥和3 - 甲基胆蒽预处理后增加,与对照小鼠相比,结合分别增加了29%和56%。用SKF 525 - A预处理小鼠可抑制结合39%。用马来酸二乙酯预处理耗尽肝谷胱甘肽会增加体内共价结合量。小鼠肝微粒体酶对PA的生物活化产生一种能够与细胞大分子发生共价相互作用的代谢产物。